Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use
Authors:
- 1 June 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 15 (9) , 1193-1203
Abstract
Clozapine was first introduced as an antipsychotic in the 1970's but a cluster of deaths, later linked to the drug's risk of agranulocytosis, led to its withdrawal in most countries. However, work in the 1980's established its unique efficacy in treatment resistant schizophrenia (TRS), which constitutes as many as 30% of those with the illness. Clozapine was reintroduced with this indication shortly thereafter, but because of this risk its use requires routine hematologic monitoring. An update is provided regarding clozapine's risk of neutropenia, agranulocytosis, and associated mortality. In addition, updates are provided on other side effects, specifically myocarditis and bowel obstruction, as evidence suggests these are more common than agranulocytosis and associated with higher mortality rates. Clozapine remains the only treatment indicated in TRS, but it is dramatically underutilized. Clearly there are serious side effects associated with its use, and while the focus has historically been on hematologic concerns, we highlight other side effects that also demand systematic monitoring. Because it is the only effective treatment option we have for TRS, though, efforts must be implemented that ensure its use in this population while maximizing safety.Keywords
This publication has 123 references indexed in Scilit:
- Practitioner attitudes to clozapine initiationActa Psychiatrica Scandinavica, 2013
- Treatment Timing vs Treatment Type in First-Episode Psychosis: A Paradigm Shift in Strategy and EffectivenessSchizophrenia Bulletin, 2012
- Is Psychiatry Ignoring Suicide?Journal of Clinical Psychopharmacology, 2012
- Subjective and Biological Weight-Related ParametersZeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 2012
- Psychopharmacology of Aggression in SchizophreniaSchizophrenia Bulletin, 2011
- Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive studyBMC Gastroenterology, 2011
- Risk Factors for Ileus in Patients with SchizophreniaSchizophrenia Bulletin, 2010
- The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database studyJournal of Psychopharmacology, 2010
- Antipsychotics‐induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance databasePharmacoepidemiology and Drug Safety, 2009
- Evaluation of Treatment-Resistant SchizophreniaSchizophrenia Bulletin, 1997